-
Approved at 2024
Annual General Meeting".
Morphosys de.
Retrieved 2024-08-28. "tafasitamab".
MorphoSys. "
MorphoSys Signs Regional License Agreement for Antibody...
- are
invalid because of obviousness." The
German biotechnology company MorphoSys generates human antibodies using its
phage display-based 'HuCal' (Human...
- cancer-centric
MorphoSys for $2.9 bln". Reuters. 5
February 2024.
Retrieved 5
February 2024. "German
regulators approve Novartis deal to buy
drugmaker Morphosys"....
- for the
global development and
commercialization of
tafasitamab with
MorphoSys. On
March 3, 2020, the
agreement received antitrust clearance and thus...
-
Energiekontor Evotec Freenet Hensoldt Infineon Technologies Jenoptik Kontron MorphoSys Nagarro SE
Nemetschek Nordex PNE AG
Qiagen SAP
Sartorius Siemens Healthineers...
-
human antibody which has been
developed by the
biotechnology company MorphoSys. It can also be
referred to as
HuCAL antibody,
HuCAL standing for Human...
- (since 2017)
Lonza Group,
Member of the
Board of
Directors (2012-2013)
MorphoSys,
Member of the
Supervisory Board (2001-2004)
Temasek Holdings, Member...
- Guangming; Kurdahi, F.J.; Bagherzadeh, N.; Filho, E.M.
Chaves (2000-06-01). "
MorphoSys: an
integrated reconfigurable system for data-parallel and com****tion-intensive...
- More Than $10 Billion". WSJ.
Retrieved 2023-12-01. AG,
MorphoSys (26
January 2016). "
MorphoSys Announces Clinical Milestone for
Start of Bayer's Phase...
- and
Health Products Portal. 4
September 2020.
Retrieved 18
March 2024. "
MorphoSys'
licensee Janssen receives ****anese
approval for
Tremfya to
treat moderate...
